756487-16-8

Upstream product

• 2418-95-3 (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid 
• 101214-43-1 Fmoc-Phe-ONSu 

Downstream Products

• 206133-42-8 [5-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-phenyl-propionylamino]-5-(4-hydroxymethyl-phenylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester 
• 756487-18-0 [(S)-5-{(S)-2-[6-(2,5-Dioxo-2,5-dihydro-pyrrol-1-yl)-hexanoylamino]-3-phenyl-propionylamino}-5-(4-hydroxymethyl-phenylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Monoclonal antibody mediated intracellular targeting of tallysomycin S 10b

The potency of tallysomycin S10b (TLM S10b) an analogue bleomycin was enhanced by up to 875-fold when it was conjugated to the internalizing antibody BR96. Attachment to the antibody is achieved via a Cathepsin B cleavable linker. The enhancement in potency is believed to be a result of cellular uptake of the conjugate upon antigen binding followed by rapid release of the drug inside the lysosome. This method provides a novel approach for increasing the potency and therapeutic index of nominally moderately-active cytotoxic agents.